2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161772
    (S)-Gebr32a 3055162-32-5 98.97%
    (S)-Gebr32a is a potent PDE4 inhibitor with IC50 values of 19.5, 2.1 µM for PDE4 cat; PDE4D3, respectively.
    (S)-Gebr32a
  • HY-161918
    SARM1-IN-3 3046146-15-7 98%
    SARM1-IN-3 (Example 30) is a SARM1 inhibitor. SARM1-IN-3 can be used in the study of chemotherapy induced peripheral neuropathy (CIPN).
    SARM1-IN-3
  • HY-162767
    KUNG65 2144469-30-5 98%
    KUNG65 is a selective inhibitor of Grp94, with a target Kd of 540 nM and at least 73 fold selectivity vs. the other Hsp90 isoforms.
    KUNG65
  • HY-162821
    LI-3948 3024591-38-3 98%
    IP6K-IN-2 (compound 29c) is an orally bioavailable and blood-brain barrier permeable IP6K inhibitor (IC50: 15.8 nM) that can be used in the study of central nervous system diseases.
    LI-3948
  • HY-163018
    Kv3.1 modulator 2 3035827-42-7 99.79%
    Kv3.1 modulator 2 (compound 4) is a Kv3.1 channels modulator with an EC50 value of 68 nM.
    Kv3.1 modulator 2
  • HY-163097
    ZCAN262 3080492-25-4 99.93%
    ZCAN262 (compound 6 ) is an AMPA modulator. ZCAN262 prevents AMPA-mediated excitotoxicity by targeting an allosteric binding site.
    ZCAN262
  • HY-163384
    (S)-CE-123 2378384-49-5 98%
    (S)-CE-123 is a potent, selective, and novel atypical dopamine transporter (DAT) inhibitor with an EC50 of 2.76 μM in uptake inhibition assays conducted in HEK293 cells stably expressing human isoforms of DAT. (S)-CE-123, a Modafinil analogue, is able to penetrate the blood–brain barrier. (S)-CE-123 improves cognitive and motivational processes in experimental animals.
    (S)-CE-123
  • HY-16346S
    Netupitant-d6 2070015-31-3 ≥98.0%
    Netupitant-d6 is the deuterium labeled Netupitant (CID-6451149), which is a highly potent and selective, orally active neurokinin-1 (NK1) receptor antagonist.
    Netupitant-d6
  • HY-163855
    KGP-25
    KGP-25 is an inhibitor of voltage-gated sodium channel 1.8 (Nav1.8), which can be used for analgesia by targeting Nav1.8 in the peripheral nervous system (PNS). KGP-25 can also target γ-aminobutyric acid subtype A receptor (GABAA) in the central nervous system (CNS) for general anesthesia.
    KGP-25
  • HY-16489A
    Terodiline hydrochloride 7082-21-5 99.78%
    Terodiline hydrochloride is an M1-selective muscarinic receptor (mAChR) antagonist with Kbs of 15, 160, 280, and 198 nM in rabbit vas deferens (M1), atria (M2), bladder (M3) and ileal muscle (M3), respectively. Terodiline hydrochloride also is a Ca2+ blocker. Terodiline hydrochloride acts as a treatment for urinary frequency and urge incontinence.
    Terodiline hydrochloride
  • HY-165578
    Neladenoson 1239234-36-6 99.95%
    Neladenoson is a potent and selective Adenosine A1 Receptor agonist. Neladenoson is promising for research of heart failure.
    Neladenoson
  • HY-16637A
    Folic acid sodium 6484-89-5 98%
    Folic acid (Vitamin B9) sodium is a orally active essential nutrient from the B complex group of vitamins. Folic acid sodium shows antidepressant-like effect. Folic acid sodium reduces the risk of neonatal neural tube defects. Folic acid sodium can be used to the research of megaloblastic and macrocytic anemias due to folic deficiency.
    Folic acid sodium
  • HY-167739
    (S,S)-Dehydroemetine 2649-50-5 98%
    (S,S)-Dehydroemetine is an antispasmodic compound with inhibitory activity on smooth muscle. (S,S)-Dehydroemetine can be used to inhibit diseases related to smooth muscle contraction.
    (S,S)-Dehydroemetine
  • HY-167745
    DDR1-IN-9 1934246-20-4 99.64%
    DDR1-IN-9 is a selective inhibitor of DDR1 with significant kinase activity suppression, exhibiting a Kd value of 4.7 nM and an IC50 value of 9.4 nM. DDR1-IN-9 demonstrates reduced potency against a diverse panel of 400 nonmutated kinases, indicating its specificity. Additionally, DDR1-IN-9 shows favorable pharmacokinetic properties and potential therapeutic effects in a model of pulmonary fibrosis.
    DDR1-IN-9
  • HY-167822
    Caramboxin 1531600-36-8 98%
    Caramboxin is a neurotoxin that can cause acute kidney injury[2].
    Caramboxin
  • HY-167840
    IMMH-010 maleate 2541982-47-0 99.80%
    IMMH-010 maleate is a prodrug that serves as a novel PD-L1 inhibitor, exhibiting potential antitumor activity for the treatment of neurological disorders and advanced malignant solid tumors. IMMH-010 maleate is rapidly converted to its active form, YPD-29B, following oral administration. IMMH-010 maleate is poised for advancing research in the field of PD-L1 inhibitors and related therapeutic applications.
    IMMH-010 maleate
  • HY-167856
    RTI-122 3034664-39-3 98%
    RTI-122 is a selective, blood-brain barrier-permeable GPR88 agonist (cAMP EC50=11 nM), with EC50 values of 11.5 nM and 155 nM for human and mouse GPR88, respectively ([35S]GTPγS assay). By activating the GPR88 receptor to regulate the cAMP signaling pathway and G protein activity, RTI-122 significantly attenuates Binge-like drinking, reduces alcohol intake, and decreases alcohol-seeking motivation. RTI-122 blocks the reinstatement of alcohol-seeking behavior without affecting water or sucrose intake. RTI-122 exhibits metabolic stability in mice (T1/2=5.8 h) and can be used to investigate alcohol use disorder.
    RTI-122
  • HY-167983
    Cx43 HC-IN-1 1840896-10-7 98%
    Cx43 HC-IN-1 (Compound D4) is a selective and orally active inhibitor of connexin hemichannels (Cx43 HC). Cx43 HC-IN-1 effectively inhibits the hemichannel activity mediated by Cx43/Cx45 in denervated skeletal muscle fibers, significantly increasing the reinnervation rate of muscle fibers by neurons. Cx43 HC-IN-1 reduces neuroinflammation and neuronal overexcitation by inhibiting hemichannels in glial cells in the brain, and alleviates epilepsy in mice. Cx43 HC-IN-1 can be used for research on epilepsy and muscle diseases.
    Cx43 HC-IN-1
  • HY-168350
    Chlorphine 6440-26-2 99.2%
    Chlorphine is a neuroactive halogenated opioid analog.
    Chlorphine
  • HY-168351
    Fluorphine 6440-42-2 99.1%
    Fluorphine is an analogue of Brorphine and can bind to μ-opioid receptor (MOR) (Ki: 12.5 nM). Fluorphine has GTPγS binding (EC50: 75 nM) and βarrestin 2 recruitment (EC50: 377 nM) activity. Fluorphine induces respiratory depressant effects.
    Fluorphine
Cat. No. Product Name / Synonyms Application Reactivity